Navigation Links
Long-term inhaled dry powder mannitol improves lung function in CF
Date:12/15/2011

Adding inhaled dry powder mannitol to standard therapy for cystic fibrosis produced sustained improvement in lung function for up to 52 weeks, according to a new study. Along with the treatment's efficacy and good safety profile, the convenience and ease of administration of mannitol treatment may improve adherence with therapy in these patients.

In the double-blind study, which was supported by Pharmaxis Limited, 318 patients were randomized to treatment with 400 mg bid inhaled mannitol or 50 mg bid inhaled mannitol (control group) for 26 weeks, followed by an additional 26 weeks of open-label active treatment. A 50 mg dose was chosen as the control because it was felt it would not be clinically effective, based on an earlier dose escalation study. Mannitol was given on top of a background of typical concomitant therapy such as recombinant human deoxyribonuclease and inhaled antibiotics.

The findings were published online ahead of print publication in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.

"Patients in the treatment group showed a 106.5 mL mean improvement in forced expiratory volume in one second (FEV1), an 8.22 percent improvement from baseline, compared with a 52.4 mL improvement (4.47 percent) in the control group," said lead author Moira L. Aitken, MD, professor of pulmonary and critical care medicine at the University of Washington Medical Center. "Forced vital capacity increased 136.3 mL in the treatment group, compared with 65.0 mL in the control group. Treated patients also experienced fewer pulmonary exacerbations than controls."

The difference in absolute FEV1 between the study and control groups approached statistical significance (p=0.059), while the difference in relative change from baseline FEV1 between groups reached significance (p=0.029). Improvements in FEV1 were maintained in the treatment group during the 26-week open-label extension phase of the study. In the control group, mean FEV1 improved 84.0 mL (6.3 percent) from baseline during the open-label phase.

Patients in the treatment and control groups experienced similar rates of adverse events. Given a possible influence of mannitol on lung microbiology, qualitative sputum microbiology was performed for Staphylococcus aureus and Pseudomonas aeruginosa during the double-blind study period. No qualitative changes in microbiology results from baseline were observed in either group.

Compliance was good in both groups, with 85.2 percent of patients in the treatment group and 88.7 percent of controls using 60 percent or more of the drug dispensed.

Although the primary end point for the study, the difference in absolute FEV1 between the treatment and control groups, did not reach significance, this may have been due to use of a single baseline visit to establish baseline FEV1 values. When baseline FEV1 values were calculated as an average of FEV1 values over two baseline visits, as in prior clinical intervention studies, the overall increase in absolute FEV1 was significantly (p=0.0008) greater in the treatment group. The 50 mg dose of mannitol used in the control group may also have had some benefit, which limited the absolute difference between groups.

"In our patients with cystic fibrosis, treatment with inhaled mannitol resulted in sustained improvements in lung function over 12 months, with a favorable safety profile," concluded Dr. Aitken. "In addition, the dry-powder inhaler used to administer mannitol is small, portable, easy to use and doesn't require thorough cleaning and disinfection after each use, which may help patients better adhere to treatment. Our results support the use of inhaled mannitol for the daily management of cystic fibrosis."


'/>"/>

Contact: Nathaniel Dunford
ndunford@thoracic.org
212-315-8620
American Thoracic Society
Source:Eurekalert

Related medicine news :

1. Ecstasy May Cause Long-Term Changes in Brain Chemistry
2. Zoledronic acid shows long-term benefit in survivorship for premenopausal ER-positive breast cancer
3. Cholesterol-Lowering Drugs Safe for Long-Term Use, Study Finds
4. Vascular risk linked to long-term antiepileptic drug therapy
5. Early, intensive therapy for type 1 diabetes prevented kidney disease in long-term study
6. Sleeping sickness drug may provide long-term protection against skin cancer
7. Elderly long-term care residents suffer cognitively during disasters
8. African-American women with gestational diabetes face high long-term diabetes risk
9. Long-Term Unemployment Can Tax Mental Health
10. For Many, Epilepsy Surgery Effective Long-Term
11. Medicare patients at risk of long-term institutionalization after hospital stay
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... ... “The Octagon of Spiritual Balances”: a guide for the Christian seeking ... published author, Pastor Bernard J. Weathers, pastor of Word of Faith Ministries, in Colonia, ... and a master degree in theology. , ““The Octagon of Spiritual Balances” exposes the ...
(Date:1/24/2017)... ... January 23, 2017 , ... The Pharmacy ... 20, with the bipartisan original co-sponsorship of nearly one-quarter of the U.S. House ... National Association of Chain Drug Stores (NACDS) strongly backs the legislation. , “NACDS ...
(Date:1/24/2017)... ... January 23, 2017 , ... ... with the acquisitions of two personal care service companies: Padre Home Health in ... effective January 1, 2017. , Well regarded in their respective markets, these two ...
(Date:1/24/2017)... ... ... The National Council of Alcoholism and Drug Dependence ( NCADD ), in ... to designate the last full week of January as National Drug and Alcohol Facts ... As a community, we can advocate for effective treatment, but also especially effective ...
(Date:1/23/2017)... ... January 23, 2017 , ... Ultimate Medical ... Education Summit to be held March 23-25, 2017 in Tampa, and reminded educators ... , The keynote speakers include Dr. Michelle R. Weise, executive director of the ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... 2017 LifeVac, the revolutionary device that has ... prevented choking deaths, welcomes Steve Way , comedian, ... team as Official Spokesperson. "We are ... said Arthur Lih , Founder and CEO of ... his mission to raise awareness about the physically disabled ...
(Date:1/23/2017)... , Jan. 23, 2017  Allergan plc, (NYSE: ... its continued support of the International Headache Academy (IHA). Designed ... neurologists and research scientists, IHA offers a three-day, intensive overview ... that Allergan has been the sole sponsor since the inception ... 2013, and iHEAD in Europe in ...
(Date:1/23/2017)... -- Varias proteínas clave que impulsan ... y el riesgo de diálisis están poco reguladas ... Resverlogix Corp. ("Resverlogix" o "la compañía") (TSX: ... en fase 1 con sede en Nueva Zelanda con ... datos demostraron unos resultados importantes en la reducción de ...
Breaking Medicine Technology: